Treatment of patients with HBV cirrhosis: Successes, unsolved problems

Bakulin I.G.; Khaĭmenova T.Iu.; Sidorova I.O.

doi:https://doi.org/

Bakulin I.G.

I.I. Mechnikov North-Western State Medical University, Sankt-Petersburg, Russia

SPIN RSCI: 5283-2032
Scopus AuthorID: 6603812937
ResearcherID: P-4453-2014
ORCID: 0000-0002-6151-2021

Khaĭmenova T.Iu.

Moskovskiĭ klinicheskiĭ nauchno-prakticheskiĭ tsentr Departamenta zdravookhraneniia Moskvy (Tsentral'nyĭ nauchno-issledovatel'skiĭ institut gastroénterologii DZG)

Sidorova I.O.

Moskovskiĭ klinicheskiĭ nauchno-prakticheskiĭ tsentr Departamenta zdravookhraneniia Moskvy (Tsentral'nyĭ nauchno-issledovatel'skiĭ institut gastroénterologii DZG)

Treatment of patients with HBV cirrhosis: Successes, unsolved problems

Authors:

Bakulin I.G., Khaĭmenova T.Iu., Sidorova I.O.

More about the authors

Journal: Therapeutic Archive. 2013;85(12): 114‑118

Read: 1335 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Bakulin IG, Khaĭmenova TIu, Sidorova IO. Treatment of patients with HBV cirrhosis: Successes, unsolved problems. Therapeutic Archive. 2013;85(12):114‑118. (In Russ.)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Hepatocellular carcinoma associated with nonalcoholic fatty liver disease. P.A. Herzen Journal of Oncology. 2024;(6):57-62

Viral infections, quality of gametes and assisted reproductive technologies: a literature review. Russian Journal of Human Reproduction. 2025;(1):44-53

Genetic diversity of hepatitis B virus in five Russian regions during the universal vaccination era: assessing the impact of new selective pressures on the spectrum of genetic and serological variants. Molecular Genetics, Microbiology and Virology. 2025;(1):38-48

Evaluation of periodontal status in patients with liver cirrhosis. Stomatology. 2025;(2):6-10

Effectiveness of etiotropic therapy in achieving recompensation of cirrhosis. Russian Journal of Evidence-Based Gastroenterology. 2025;(2):68-77

Abstract:

Annually 0.5-1 million people die from terminal liver injuries or hepatocellular carcinoma, which are associated with hepatitis B virus (HBV); 5-10% of liver transplantations are performed due to the outcomes of HBV infections. All patients with liver cirrhosis in the outcome of replication-phase chronic hepatitis B need antiviral therapy. At present, there is convincing evidence for amelioration of hepatic fibrosis and cirrhosis, a reduction in the risk for the decompensation of liver function and the development of hepatocellular carcinoma, and an increase in survival rates in patients with HBV cirrhosis long treated with nucleotide analogues. Adequate selection of patients to be treated with antiviral drugs from different groups enables the most successful results and optimizes the economic costs of treatment.

Keywords:

liver cirrhosis

hepatocellular carcinoma

HBV hepatitis

hepatitis B virus

antiviral therapy

Authors:

Bakulin I.G.

I.I. Mechnikov North-Western State Medical University, Sankt-Petersburg, Russia

SPIN RSCI: 5283-2032
Scopus AuthorID: 6603812937
ResearcherID: P-4453-2014
ORCID: 0000-0002-6151-2021

Khaĭmenova T.Iu.

Moskovskiĭ klinicheskiĭ nauchno-prakticheskiĭ tsentr Departamenta zdravookhraneniia Moskvy (Tsentral'nyĭ nauchno-issledovatel'skiĭ institut gastroénterologii DZG)

Sidorova I.O.

Moskovskiĭ klinicheskiĭ nauchno-prakticheskiĭ tsentr Departamenta zdravookhraneniia Moskvy (Tsentral'nyĭ nauchno-issledovatel'skiĭ institut gastroénterologii DZG)

Close metadata

References:

Znoiko O.O. Rol' protivovirusnoi terapii v modifikatsii estestvennogo techeniya khronicheskogo gepatita V. XI nauch.-prakt konf. "Infektsionnye bolezni i antimikrobnye sredstva". Tez dokl 2013: 21-22.
Bakulin I.G. Nukleozidnye analogi v lechenii tsirroza pecheni virusnoi HBV-etiologii. Ros zhurn gastroenterol, gepatol, koloproktol 2009; 1: 22-27.
Fattovich G., Stroffolini T., Zagni I., Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: 35-50.
Lupberger J., Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol 2007; 13 (1): 74-81.
Perz J.F., Armstrong G.L., Farrington L.A. et al. The contribution of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006; 45: 529-538.
Torresi J., Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 2000; 118 (2 Suppl 1):83-103.
Pavlov Ch.S., Bakulin I.G. Virus gepatita V - osnovnoi etiologicheskii faktor khronicheskogo virusnogo gepatita, tsirroza pecheni i gepatotsellyulyarnoi kartsinomy. Rus med zhurn 2008; 4: 157-160.
Chen C.-J., Yang H.-I., Su J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295 (1): 65-73.
EASL Clinical Practice Guidelines: management of chronic hepatitis B. European Association For The Study Of The Liver. J Hepatol 2009; 50 (2): 227-242.
Abdurakhmanov D.T. Protivovirusnaya terapiya i regress fibroza pecheni pri khronicheskom gepatite V. RZhGGK 2010; 1: 14-20.
Lok A. Practical guidelines of the AASLD: AASLD Practice Guidelines. Hepatology 2009; 50 (3): 231-232.
Zoulim E., Radenne S., Ducerf C. Management of patients with decompensated hepatitis B virus associated cirrhosis. Liver Transplant 2008; 4: 1-7.
Lok A.S.F., McMahon B.J. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 1-36.
Papatheodoridis G., Petraki K., Cholongitas E. et al. Impact of interferon-alpha therapy on liver fibrosis progression in patients with HBeAg-negative chronic hepatitis B. J Viral Hepatol 2005; 12 (2): 199-206.
Bakulin I.G., Sandler Yu.G. Interferonoterapiya pri khronicheskom gepatite V: za i protiv. Klin farmakol i ter. Prilozhenie "Gepatol forum" 2010; 1: 5-10.
Isakov V.A. Markery effektivnosti terapii khronicheskogo gepatita V: vchera, segodnya, zavtra. Klin gastroenterol i gepatol 2009; 5: 335-338.
Gish R.G., Chang T.T., Lai C.L. et al. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. J Viral Hepat 2010; 17 (1): 16-22.
Schiff E., Simsek H., Lee W. et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008; 103 (11): 2776-2783.
Poynard T., Zoulim F., Ratziu V. et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100: 1970-1980.
Chang T.T., Gish R.G., de Man R. et al. A comparison of entecavir and lamivudine for HBeAg positive chronic hepatitis B. N Engl J Med 2006; 354: 1001-1010.
Lai C.L., Gane E., Liaw Y.F. et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588.
Lai C.L., Shouval D., Lok A.S. et al. Entecavir versus lamivudine for patients with HBeAg negative chronic hepatitis B. N Engl J Med 2006; 354: 1011-1020.
Liaw Y., Chang T., Wu S. et al. Long-term entecavir therapy results in reversal of fibrosis/cirrhosis and continued histologic improvement in patients with HBeAg(+) and (-) chronic hepatitis b: results from studies ETV-022, -027 and -901. Hepatology 2008; 48: 706A.
Chang T.T., Liaw Y.F., Wu S.S. et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52 (3): 886-893.
Takehara T., Hayashi N., Takaguchi K. et al. Efficacy and safety of 3 years treatment with entecavir in Japanese nucleoside-naïve patients with chronic hepatitis B. Hepatol Intern 2008; 2 (1): 97.
Zoutendijk R.J., Reijnders G., Zoulim F. et al. Virological response to entecavir is associated with a lower probability of disease progression: results from 377 chronic hepatitis B patients. AASLD 2011, San Francisco, USA. Poster 240.